We're attending AACR, Florida in April 2023. Schedule a meeting with the team.

Mergers & Acquisitions for the life science sector

We offer a truly end-to-end service for the evolution of your company from growth to exit strategy, be that purchasing other assets or selling your own.

Sales Growth 5
Pivotal Links

Mergers & Acquisitions

Since 2013, Pivotal Scientific has supported the biotechnology industry within the Mergers and Acquisitions field, assisting in over 20 transactions to date. Our specialist M&A team brings collective skills and experience of over 80 years within the biotech sector; uniquely combining in-depth knowledge of technology with personal experience of distribution, marketing strategy & implementation, along with M&A. As two of our team members are themselves biotech investors and directors, we offer services backed by knowledge that only experience can bring.

Pivotal Links 213116 1030x709

Why choose Pivotal Scientific for your Mergers & Acquisitions?

Pivotal Scientific is different because we combine deep industry knowledge and broad M&A experience in biotechnology. We believe that, in order to help companies, we first have to understand them. Our team has experience in setting up companies, growing companies and selling companies, all within the Biotechnology sector. We use this direct personal experience to support our clients in developing and executing their M&A strategy.

  • Since 2019, we have completed 60 biotechnology strategy reviews, undertaken 20+ sell side transactions & 30+ buy side projects.

  • Within buy side, we typically support commercial due diligence, strategic planning, future M&A planning, integration, and operating model planning.

  • We are able to support both buyers and sellers across all continents including UK, Europe, USA, Asia and Africa. Our experience and expertise lies within the small to medium enterprise sector.

  • Within sell-side we support valuation, preparation of CIM, selection, and approach to potential buyers. We can manage and consult on the end-to-end process or allow you to take the process forward yourselves following introductions.

The M&A Team

Tim Bernard

Tim Bernard


With over 30 years of experience within the biotech sector, specializing in antibodies and proteins, Tim has provided distribution, marketing strategy & implementation to over 100 life science companies. He has completed 20 M&A transactions on both buy and sell side, including the ownership and subsequent sale of his own company Serotec limited, along with 4 other antibody companies. Tim is a former Director at Absolute Antibody Limited and remains an active investor, non-executive director, and Chair for 3 further biotech companies. He is additionally co–owner of 2BScientific Ltd., the successful UK life science distributor.

Stevan Hoyle

M&A Strategy

Stevan offers specialist competences in M&A, sales & marketing, strategy & operating models. Since 2013, he has completed over 30 M&A transactions on buy and sell side, both at Pivotal Scientific and within the IT/Telecommunications sector. A director at Vodafone group between 1999 and 2016, Stevan established businesses in USA, India, Africa, SE. Asia, China and Middle east. He now brings his considerable experience and knowledge of go-to-market (GTM) strategies to assist biotech companies in the assessment and development of their own approaches to market. His understanding of the synergies and opportunities between companies and adjacent markets bring a unique angle to our M&A and CDD capabilities. Stevan is an active NED and Chair for 3 biotech companies and strategy advisor to Citrix Europe. He is a former Director at Absolute Antibody Limited

Stevan Hoyle
Sian Bolitho

Sian Bolitho

Scientific Officer

Sian has worked predominantly as a product and commercial manager for the last 18 years.  Her focus has always been to identify cutting edge technology, applications and novel scientific companies, working with them to present their products to the wider research and IVD markets.  With a skillset focused on bringing these technologies to new markets and working to build diverse, integrated portfolios for platforms, Sian’s experience, combined with her scientific knowledge, places her well to work within our expanding Mergers & Acquisitions team.